[Federal Register Volume 88, Number 83 (Monday, May 1, 2023)]
[Notices]
[Pages 26561-26562]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2023-09176]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2023-D-0451]
Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient
Statements; Draft Guidance for Industry; Availability; Agency
Information Collection Activities; Proposed Collection; Comment
Request; Reopening of the Comment Period
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice of availability; reopening of the comment period.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA or we) is reopening the
comment period for the draft guidance entitled ``Labeling of Plant-
Based Milk Alternatives and Voluntary Nutrient Statements; Guidance for
Industry,'' which was announced in the Federal Register of February 23,
2023. We are taking this action in response to requests for an
extension to allow interested persons additional time to submit
comments.
DATES: FDA is reopening the comment period on the draft guidance
published February 23, 2023 (88 FR 11449). Submit either electronic or
written comments on the draft guidance by July 31, 2023, to ensure that
we consider your comment on the draft guidance before we begin work on
the final version of the guidance.
ADDRESSES: You may submit comments on any guidance at any time as
follows.
Electronic Submissions
Submit electronic comments in the following way:
Federal eRulemaking Portal: https://www.regulations.gov.
Follow the instructions for submitting comments. Comments submitted
electronically, including attachments, to https://www.regulations.gov
will be posted to the docket unchanged. Because your comment will be
made public, you are solely responsible for ensuring that your comment
does not include any confidential information that you or a third party
may not wish to be posted, such as medical information, your or anyone
else's Social Security number, or confidential business information,
such as a manufacturing process. Please note that if you include your
name, contact information, or other information that identifies you in
the body of your comments, that information will be posted on https://www.regulations.gov.
If you want to submit a comment with confidential
information that you do not wish to be made available to the public,
submit the comment as a written/paper submission and in the manner
detailed (see ``Written/Paper Submissions'' and ``Instructions'').
Written/Paper Submissions
Submit written/paper submissions as follows:
Mail/Hand Delivery/Courier (for written/paper
submissions): Dockets Management Staff (HFA-305), Food and Drug
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
For written/paper comments submitted to the Dockets
Management Staff, FDA will post your comment, as well as any
attachments, except for information submitted, marked and identified,
as confidential, if submitted as detailed in ``Instructions.''
Instructions: All submissions received must include the Docket No.
FDA-2023-D-0451 for ``Labeling of Plant-Based Milk Alternatives and
Voluntary Nutrient Statements; Draft Guidance for Industry;
Availability; Agency Information Collection Activities; Proposed
Collection; Comment Request.'' Received comments will be placed in the
docket and, except for those submitted as ``Confidential Submissions,''
publicly viewable at https://www.regulations.gov or at the Dockets
Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-
402-7500.
Confidential Submissions--To submit a comment with
confidential information that you do not wish to be made publicly
available, submit your comments only as a written/paper submission. You
should submit two copies total. One copy will include the information
you claim to be confidential with a heading or cover note that states
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' We will review
this copy, including the claimed confidential information, in our
consideration of comments. The second copy, which will have the claimed
confidential information redacted/blacked out, will be available for
public viewing and posted on https://www.regulations.gov. Submit both
copies to the Dockets Management Staff. If you do not wish your name
and contact information to be made publicly available, you can provide
this information on the cover sheet and not in the body of your
comments and you must identify this information as ``confidential.''
Any information marked as ``confidential'' will not be disclosed except
in accordance with 21 CFR 10.20 and other applicable disclosure law.
For
[[Page 26562]]
more information about FDA's posting of comments to public dockets, see
80 FR 56469, September 18, 2015, or access the information at: https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
Docket: For access to the docket to read background documents or
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in
the heading of this document, into the ``Search'' box and follow the
prompts and/or go to the Dockets Management Staff, 5630 Fishers Lane,
Rm. 1061, Rockville, MD 20852, 240-402-7500.
FOR FURTHER INFORMATION CONTACT: Jeanmaire Hryshko, Center for Food
Safety and Applied Nutrition, Food and Drug Administration, 5001 Campus
Dr., College Park, MD 20740, 240-402-2371; or Philip Chao, Center for
Food Safety and Applied Nutrition, Office of Regulations and Policy
(HFS-024), Food and Drug Administration, 5001 Campus Dr., College Park,
MD 20740, 240-402-2378.
SUPPLEMENTARY INFORMATION: In the Federal Register of February 23, 2023
(88 FR 11449), we published a notice of availability for a draft
guidance entitled ``Labeling of Plant-Based Milk Alternatives and
Voluntary Nutrient Statements; Draft Guidance for Industry;
Availability; Agency Information Collection Activities; Proposed
Collection; Comment Request.'' This action opened a docket with a 60-
day comment period.
We have received requests for a 90-day extension of the comment
period for the draft guidance. We have concluded that it is reasonable
to reopen the comment period for 90 days, until July 31, 2023. We are
reopening the comment period because the request for an extension of
the comment period arrived too late for us to extend the comment
period. We believe that an additional 90 days allows adequate time for
interested persons to submit comments.
Dated: April 26, 2023.
Lauren K. Roth,
Associate Commissioner for Policy.
[FR Doc. 2023-09176 Filed 4-28-23; 8:45 am]
BILLING CODE 4164-01-P